Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Urologic Oncology|August 28, 2014
Assessing the quality of studies on the diagnostic accuracy of tumor markersPeter J Goebell, Ashish M Kamat, Richard J Sylvester, et al.
International Journal of Cancer|October 29, 2025
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARATPeter J Goebell, Martin Bögemann, Arnd Nusch, et al.
Oncology Research and Treatment|April 2, 2014
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practiceLothar Bergmann, Jochaim Beck, Kathrin Bothe, et al.
European Urology Oncology|May 8, 2025
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder CancerBernd J Schmitz-Dräger, Ekkehardt Bismarck, Florian Roghmann, et al.
European Urology Oncology|October 23, 2018
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer PatientsStephen B Williams, Ashish M Kamat, Karim Chamie, et al.
Urologic Oncology|October 23, 2022
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuriaEva Charlotte Kuckuck, Jörg Hennenlotter, Tilman Todenhöfer, et al.
Urologic Oncology|February 25, 2024
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancerNatalya Benderska-Söder, Thorsten Ecke, Lisa Kleinlein, et al.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
Urologic Oncology|October 13, 2014
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancerAshish M Kamat, Antonia Vlahou, John A Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer AgentsPauline Dürr, Katja Schlichtig, Carolin Kelz, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Urologic Oncology|August 28, 2014
Assessing the quality of studies on the diagnostic accuracy of tumor markersPeter J Goebell, Ashish M Kamat, Richard J Sylvester, et al.
International Journal of Cancer|October 29, 2025
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARATPeter J Goebell, Martin Bögemann, Arnd Nusch, et al.
Oncology Research and Treatment|April 2, 2014
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practiceLothar Bergmann, Jochaim Beck, Kathrin Bothe, et al.
European Urology Oncology|May 8, 2025
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder CancerBernd J Schmitz-Dräger, Ekkehardt Bismarck, Florian Roghmann, et al.
European Urology Oncology|October 23, 2018
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer PatientsStephen B Williams, Ashish M Kamat, Karim Chamie, et al.
Urologic Oncology|October 23, 2022
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuriaEva Charlotte Kuckuck, Jörg Hennenlotter, Tilman Todenhöfer, et al.
Urologic Oncology|February 25, 2024
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancerNatalya Benderska-Söder, Thorsten Ecke, Lisa Kleinlein, et al.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
Urologic Oncology|October 13, 2014
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancerAshish M Kamat, Antonia Vlahou, John A Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2021
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer AgentsPauline Dürr, Katja Schlichtig, Carolin Kelz, et al.
Pageof 11